Delta-9-THC Amino Acid Ester Prodrugs for Enhanced Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery methods for delta-9-THC face challenges such as poor bioavailability, rapid metabolism, and adverse effects due to its lipophilic nature, limiting its therapeutic efficacy and consistency in treating conditions like chemotherapy-induced nausea, glaucoma, and pain.
Innovation Solution
Development of delta-9-THC amino acid esters, which are more hydrophilic and stable, formulated into suppositories, transmucosal patches, and ophthalmic preparations to enhance bioavailability and reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If delta-9-THC is administered orally, then it provides therapeutic effects, but its bioavailability is severely limited due to poor solubility in gastro-intestinal fluids and rapid metabolism
Solution Approach 1:
The patent modifies the chemical parameters of THC by converting it into amino acid ester prodrugs (such as THC-valinate, THC-leucinate, THC-phenylalanine). These prodrugs have altered solubility characteristics and metabolic stability, enabling them to dissolve better in gastro-intestinal fluids and resist rapid hepatic metabolism, thereby improving bioavailability while maintaining therapeutic efficacy
Solution Approach 2:
The patent introduces amino acid esters as intermediary compounds that serve as prodrugs. These intermediaries are first absorbed and metabolized in the body to release the active THC molecule, bypassing the direct solubility and metabolism issues of pure THC. The amino acid ester moiety acts as a carrier that improves pharmacokinetic properties before releasing the therapeutic agent
2Object-affected harmful factors
If delta-9-THC is formulated as lipophilic compound, then it has potential therapeutic activities, but its solubility in gastro-intestinal fluids is severely limited
Solution Approach 1:
The patent changes the physicochemical parameters of THC by esterifying it with amino acids. This chemical modification transforms the highly lipophilic THC (log P around 4.0) into prodrugs with reduced lipophilicity and improved aqueous solubility, while preserving the core THC structure necessary for therapeutic activity at the cannabinoid receptors
3Reliability
If delta-9-THC is administered to achieve therapeutic blood plasma levels, then it provides therapeutic effect, but it produces significant adverse effects due to rapid metabolism to 11-OH-THC
Solution Approach 1:
The patent employs preliminary chemical action by pre-modifying THC into stable amino acid ester prodrugs. These prodrugs are designed to be metabolized in a controlled manner in the body, with the amino acid ester bond being cleaved to release THC. This preliminary modification allows for controlled release and reduced formation of the undesirable 11-OH-THC metabolite, thereby reducing adverse effects while maintaining therapeutic efficacy
Data Source
AI summary
Suppository, hot melt and ophthalmic formulations containing amino esters of the formulae (I), (II) and (III), where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof.